PRE — Prenetics Global Limited

Summary of Prenetics Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $36.6 million, up 457% year-over-year and 55% sequentially.
• Full Year Revenue: $92.4 million, a 480% increase from 2024.
• Q4 Gross Profit: $21.7 million, with a gross margin of 59%.
• Full Year Gross Profit: $48.9 million, a 428% increase.
• Adjusted EBITDA Loss: Q4 loss of $2.3 million (improved by 70.4% year-over-year); full year loss of $13 million (27% improvement).
• IM8 Revenue: $27.4 million in Q4 and $60.1 million for the full year, with a gross margin of 63%.

2. Strategic Updates and Business Highlights

• IM8 Launch: The premium consumer health brand co-founded with David Beckham achieved a $120 million annualized revenue run rate in its first year.
• Divestitures: Completed the sale of noncore assets, including ACT Genomics ($72 million), Europa business (all-stock deal valued at $30 million), and a 35% stake in Insighta to Tencent for $70 million. This has strengthened the balance sheet, now holding $171 million in liquidity with zero debt.
• Customer Acquisition: The introduction of quarterly subscriptions has doubled the average order value from $110 to approximately $233, with an 80% subscription rate among new customers.
• New Board Member: Dr. Darshan Shah, an expert in longevity and performance optimization, joined the Board to support IM8's growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected IM8 revenue of $180 million to $200 million, representing nearly 300% year-over-year growth.
• Gross Margin Target: Approximately 60% for full year 2026.
• Adjusted EBITDA Loss: Expected to be between $16 million and $20 million for 2026, with a path to adjusted EBITDA profitability by Q4 2027.

4. Bad News, Challenges, or Points of Concern

• Adjusted EBITDA Loss: While improving, the company still anticipates losses in the near term as it invests in growth.
• Customer Acquisition Costs: Although CAC has remained stable, there is potential for increased competition and market saturation, which could impact future CAC and profitability.
• Market Risks: The company is heavily reliant on the success of IM8 and must navigate competitive pressures in the health supplement market.

5. Notable Q&A Insights

• Customer Acquisition Costs: The current CAC is approximately $130, with a payback period of 3.4 months. The company plans to diversify marketing channels to enhance customer acquisition.
• Product Launches: Two new SKUs are expected by the end of Q4 2026, targeting large addressable markets, but these are not included in the current revenue guidance.
• International Expansion: Localization efforts are anticipated to yield a 10-15% revenue uplift in targeted markets.
• AI Utilization: The company is leveraging AI for digital marketing and operational efficiencies, including ad optimization and customer engagement.

Overall, Prenetics has demonstrated significant growth and strategic transformation in 2025, positioning itself as a leader in the consumer health sector with a strong focus on its IM8 brand. However, the company faces challenges related to profitability and market competition as it continues to scale.